Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status

P Grivas; ER Plimack; AV Balar; D Castellano; PH O'Donnell; J Bellmunt; T Powles; NM Hahn; Ronald de Wit; DF Bajorin; MC Ellison; TL Frenkl; JL Godwin; J Vuky

doi:10.1016/j.euo.2020.02.009

Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status

P Grivas, ER Plimack, AV Balar, D Castellano, PH O'Donnell, J Bellmunt, T Powles, NM Hahn, Ronald de Wit, DF Bajorin, MC Ellison, TL Frenkl, JL Godwin, J Vuky

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

34 Citations (Scopus)

20 Downloads (Pure)

Original language	English
Pages (from-to)	351-359
Number of pages	9
Journal	European urology oncology
Volume	3
Issue number	3
DOIs	https://doi.org/10.1016/j.euo.2020.02.009
Publication status	Published - 2020

Research programs

EMC OR-01

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.euo.2020.02.009

Repub_128514_O-A.pdfFinal published version, 652 KB

http://hdl.handle.net/1765/128514

Cite this

Grivas, P., Plimack, ER., Balar, AV., Castellano, D., O'Donnell, PH., Bellmunt, J., Powles, T., Hahn, NM., de Wit, R., Bajorin, DF., Ellison, MC., Frenkl, TL., Godwin, JL., & Vuky, J. (2020). Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status. European urology oncology, 3(3), 351-359. https://doi.org/10.1016/j.euo.2020.02.009

@article{56c0af17324445fca4405bf6d11176bd,

title = "Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status",

author = "P Grivas and ER Plimack and AV Balar and D Castellano and PH O'Donnell and J Bellmunt and T Powles and NM Hahn and {de Wit}, Ronald and DF Bajorin and MC Ellison and TL Frenkl and JL Godwin and J Vuky",

year = "2020",

doi = "10.1016/j.euo.2020.02.009",

language = "English",

volume = "3",

pages = "351--359",

journal = "European urology oncology",

issn = "2588-9311",

publisher = "Elsevier",

number = "3",

}

Grivas, P, Plimack, ER, Balar, AV, Castellano, D, O'Donnell, PH, Bellmunt, J, Powles, T, Hahn, NM, de Wit, R, Bajorin, DF, Ellison, MC, Frenkl, TL, Godwin, JL & Vuky, J 2020, 'Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status', European urology oncology, vol. 3, no. 3, pp. 351-359. https://doi.org/10.1016/j.euo.2020.02.009

TY - JOUR

T1 - Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status

AU - Grivas, P

AU - Plimack, ER

AU - Balar, AV

AU - Castellano, D

AU - O'Donnell, PH

AU - Bellmunt, J

AU - Powles, T

AU - Hahn, NM

AU - de Wit, Ronald

AU - Bajorin, DF

AU - Ellison, MC

AU - Frenkl, TL

AU - Godwin, JL

AU - Vuky, J

PY - 2020

Y1 - 2020

U2 - 10.1016/j.euo.2020.02.009

DO - 10.1016/j.euo.2020.02.009

M3 - Article

C2 - 32423837

SN - 2588-9311

VL - 3

SP - 351

EP - 359

JO - European urology oncology

JF - European urology oncology

IS - 3

ER -